Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to compare the efficacy and safety of pazopanib in combination
with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic
breast cancer whose tumors overexpress the ErbB2 protein.